Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naive and relapsed/refractory patients with chronic lymphocytic leukemia

被引：0
|
作者：
Andersson, Maria
Mulder, Tom
Heimersson, Kia
Sonnert-Husa, Sonja
Giertz, Annika
Karlsson, Claes
Lundin, Jeanette
Hansson, Lotta
Osterborg, Anders
Palma, Marzia
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553105
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [41] Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up
    Woyach, Jennifer A.
    Rogers, Kerry A.
    Bhat, Seema
    Blachly, James
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min Hui
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S281 - S281
  • [42] Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/ Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1 /2 ACE-CL-001 Study
    Covey, Todd
    Gulranjani, Michael
    Cheung, Jean
    Bibikova, Elena
    Clevenger, Tracy
    Krantz, Fanny
    Pan, Karen
    Yamaguchi, Kyoko
    De Jong, Anouk
    Van Lith, Bart
    Mittag, Diana
    Izumi, Raquel
    Byrd, John C.
    Wierda, William G.
    O'Brien, Susan M.
    Furman, Richard R.
    Kaptein, Allard
    BLOOD, 2017, 130
  • [43] BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
    Blombery, Piers
    Thompson, Ella R.
    Chen, Xiangting
    Nguyen, Tamia
    Anderson, Mary Ann
    Westerman, David Alan
    Seymour, John F.
    Tam, Constantine S.
    Dengler, Michael A.
    Huang, David C. S.
    Wei, Andrew
    Roberts, Andrew W.
    BLOOD, 2020, 136
  • [44] The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival
    van Eijck, Casper W. F.
    Ju, Jie
    van 't Land, Freek R.
    Verheij, Maaike
    Li, Yunlei
    Stubbs, Andrew
    Doukas, Michael
    Lila, Karishma
    Heij, Lara R.
    Wiltberger, Georg
    Alonso, Lola
    Malats, Nuria
    Koerkamp, Bas Groot
    Vietsch, Eveline E.
    van Eijck, Casper H. J.
    PANCREATOLOGY, 2024, 24 (07) : 1057 - 1065
  • [45] Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
    Shadman, Mazyar
    Munir, Talha
    Robak, Tadeusz
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Giannopoulos, Krzysztof
    Simkovic, Martin
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia A.
    Opat, Stephen S.
    Ciepluch, Hanna
    Greil, Richard
    Hanna, Merit
    Tani, Monica
    Trneny, Marek
    Brander, Danielle
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Tedeschi, Alessandra
    de Guibert, Sophie
    Tumyan, Gayane
    Laribi, Kamel
    Garcia-Marco, Jose A.
    Li, Jian-Yong
    Tian, Tian
    Liu, Yu
    Korolkiewicz, Roman
    Szeto, Andy
    Tam, Constantine S.
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [46] Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
    Visentin, Andrea
    Mauro, Francesca Romana
    Scarfo, Lydia
    Gentile, Massimo
    Farina, Lucia
    Reda, Gianluigi
    Ferrarini, Isacco
    Proietti, Giulia
    Derenzini, Enrico
    Cibien, Francesca
    Vitale, Candida
    Sanna, Alessandro
    Pietrasanta, Daniela
    Marchetti, Monia
    Murru, Roberta
    Rigolin, Gian Matteo
    Sportoletti, Paolo
    Trimarco, Valentina
    Cavarretta, Chiara Adele
    Angotzi, Francesco
    Cellini, Alessandro
    Ruocco, Valeria
    Zatta, Ivan
    Laurenti, Luca
    Molica, Stefano
    Coscia, Marta
    Ghia, Paolo
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : E237 - E240
  • [47] Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
    Solman, Isabelle G.
    Blum, Lisa K.
    Hoh, Hana Y.
    Kipps, Thomas J.
    Burger, Jan A.
    Barrientos, Jacqueline C.
    O'Brien, Susan
    Mulligan, Stephen P.
    Kay, Neil E.
    Hillmen, Peter
    Byrd, John C.
    Lal, Indu D.
    Dean, James P.
    Mongan, Ann
    LEUKEMIA RESEARCH, 2020, 97
  • [48] LDH as Predictive Parameter in Treatment-Naive Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12
    Autore, Francesco
    Strati, Paolo
    Innocenti, Idanna
    Corrente, Francesco
    Trentin, Livio
    Cortelezzi, Agostino
    Visco, Carlo
    Coscia, Marta
    Cuneo, Antonio
    Gozzetti, Alessandro
    Mauro, Francesca Romana
    Frustaci, Anna Maria
    Gentile, Massimo
    Morabito, Fortunato
    Molica, Stefano
    Falcucci, Paolo
    D'Arena, Giovanni
    Murru, Roberta
    Vincelli, Donatella
    Efremov, Dimitar G.
    Visentin, Andrea
    Reda, Gianluigi
    Tisi, Maria Chiara
    Vitale, Candida
    Rigolin, Gian Matteo
    Ferretti, Antonietta
    Sica, Simona
    Foa, Robin
    Ferrajoli, Alessandra
    Laurenti, Luca
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S213 - S213
  • [49] Phase I study of ibrutinib in Japanese patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shibayama, Hirohiko
    Teshima, Takanori
    Choi, Ilseung
    Hatake, Kiyohiko
    Sekiguchi, Naohiro
    Yoshinari, Nozomi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (04) : 179 - 186
  • [50] Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: Mature Results From a Phase 2 Study Demonstrating Durable Remissions and Long-Term Tolerability
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 6 - 7
12345